Thai Meiji Pharmaceutical Co. Ltd.

Name

Thai Meiji Pharmaceutical Co. Ltd.

Legal name

Thai Meiji Pharmaceutical Co., Ltd.

Website

https://thaimeiji.co.th

Company type

Private

Founded year

1979

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

akta.pro secondary industries

Manufacturing, Private Label & Co-Manufacturing for Animal Diets (HLAMAHAO), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Antibiotic fermentation production
• Sterile injectable manufacturing
• Veterinary pharmaceuticals

Headquarters

HQ city

Bangkok

HQ country

Thailand

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Human Pharmaceutical Products: Manufacturing and distribution of human pharmaceutical products including antibiotics, cardiovascular and metabolic drugs, bone and joint medications, gastrointestinal treatments, nephrology drugs, and hematology therapeutics. Products are supplied in both original research and generic formulations, available as injectable and oral medications.
2. Active Pharmaceutical Ingredients (API): Production of active pharmaceutical ingredients using fermentation technology from Japan. The company manufactures antibiotic APIs for both internal use and external supply to pharmaceutical markets.
3. Veterinary Pharmaceuticals: Manufacturing and supply of veterinary pharmaceutical products for animal health, welfare, and livestock productivity. Products are manufactured under Meiji's stringent quality standards.
4. International Trade: Import and export of pharmaceutical products to international markets including Japan, Taiwan, and ASEAN countries. The company has licensing capabilities for pharmaceutical products from international companies.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Core offering

Thai Meiji Pharmaceutical manufactures and distributes a broad portfolio of human and veterinary pharmaceutical products, spanning antibiotics, cardiovascular and metabolic drugs, bone and joint medications, gastrointestinal treatments, nephrology, and hematology therapeutics. The company operates the only plant in Southeast Asia with fermentation-based, fully integrated production from Active Pharmaceutical Ingredients (API) to finished sterile injectables and oral dosage forms, using Japanese-origin microorganism strains and technology licensed from its parent Meiji Seika Pharma. It serves both domestic Thai public and private healthcare sectors and international markets through export partnerships.

Product overview

Thai Meiji Pharmaceutical Co., Ltd. operates as a fully integrated pharmaceutical manufacturing company offering a comprehensive portfolio of products and services. The company operates the only plant in Southeast Asia to incorporate fermentation in its manufacturing process, producing Active Pharmaceutical Ingredients (API) through advanced Japanese fermentation technology. The product portfolio includes sterile products (injections, sterile powders), non-sterile products (tablets, capsules, vials, suspensions), veterinary formulations, and human pharmaceuticals covering antibiotics, cardiovascular/metabolic, bone & joint, gastrointestinal, nephrology, and hematology therapeutic areas. The company supplies both original research pharmaceuticals and generic products. Thai Meiji also provides quality control and quality assurance services, and operates an international business segment trading with Japan, Taiwan, and ASEAN countries.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (API) Manufacturing

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered parent, core and flagship.

• Meiji Seika Pharma Co., Ltd.parentStrategic or Co-development Partner · 1 November 1979Parent company and strategic partner from Japan. Thai Meiji Pharmaceutical was established as a joint venture between Thai partners and Meiji Seika Pharma. The parent company provides advanced pharmaceutical technology, manufacturing expertise, and ongoing strategic guidance. Meiji Seika Pharma has over 100 years of pharmaceutical innovation experience and pioneered antibiotic development in 1946.
• International Partners (Japan, Taiwan, ASEAN)coreChannel Partner/ Reseller/ DistributorLong-standing partnerships with pharmaceutical companies in Japan, Taiwan, and throughout ASEAN for import and export of high-quality pharmaceutical products. These partnerships enable access to regional markets and facilitate technology exchange.
• Meiji Pharma Asia Pte. Ltd.flagshipStrategic or Co-development PartnerNewly established subsidiary in Singapore serving as a regional hub for Asian operations. This subsidiary strengthens the company's presence in Southeast Asia and supports expansion strategy following the ASEAN Economic Community formation.

Scale indicators3 records

Recent moves8 records

Expansion highlights4 records

Direct peers

• Greater Pharma: Thai pharmaceutical manufacturer focused on generics, injectables, and consumer health. Competes with Thai Meiji in the domestic Thai generics and hospital supply channels.
• Daiichi Sankyo: Japanese pharmaceutical major with cardiovascular and specialty therapeutics portfolios and active Southeast Asian manufacturing/sales operations — overlap with Thai Meiji's cardiometabolic and specialty injectable focus.
• Meiji Seika Pharma: Parent company of Thai Meiji Pharmaceutical and Japan's originator of the fermentation technology and antibiotic pipeline that Thai Meiji operates. Most directly comparable as the source of strains, GMP know-how, and therapeutic-area strategy.
• Otsuka Pharmaceutical: Japanese-headquartered pharmaceutical manufacturer with established ASEAN manufacturing and distribution operations, including sterile injectables and specialty therapeutics, comparable in scale and Asian-market orientation.
• Biolab (Thailand): Thai domestic pharmaceutical manufacturer producing antibiotics, injectables, and specialty generics. Direct head-to-head competitor in Thailand's hospital tender market.
• Astellas Pharma: Japanese pharma with manufacturing presence across Asia and a strong specialty/hospital product portfolio. Comparable in Japan-to-ASEAN technology transfer model and emphasis on specialty therapeutics.

Broad incumbents

• Sanofi (Thailand): Global pharmaceutical incumbent with established Thai operations across cardiovascular, vaccines, and specialty therapeutics. Competes for the same public and private hospital channel as Thai Meiji.
• Takeda Pharmaceutical: Global Japanese pharmaceutical incumbent with established Thai and broader ASEAN operations across specialty, GI, and rare disease therapeutics — a broader-portfolio incumbent competing for the same hospital channel.

Regional players

• Zuellig Pharma: Asia's largest pharmaceutical distributor, headquartered in Singapore and serving 16 markets. Comparable as the dominant regional pharma distribution infrastructure competing for the same hospital and pharmacy channels.
• DKSH Holding: Swiss-headquartered market expansion services firm with a major Healthcare (pharmaceutical distribution) business across Thailand and ASEAN. Comparable as a channel partner/distributor serving the same hospital segment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/thai-meiji-pharmaceutical-co-ltd-

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Thai Meiji Pharmaceutical Co. Ltd.